Table 2 Docetaxel nanoformulations and use for chemotherapy
Drug(s) | Formulation type | Formulation ingredients | Study type | Cancer type | Dosing and administration | Remarks | References |
|---|---|---|---|---|---|---|---|
Docetaxel | Polymeric micelle | Poly (ethylene oxide)-block-poly (styrene oxide) (PEO-b-PSO) and PEO-b-poly (butylene oxide) (PEO-b-PBO) | In vitro | Prostate cancer cell line | Not specified | Solubilization was better with PSO than PBO copolymers | Elsabahy et al. (2007) |
Docetaxel | Polymeric micelle | Poly(ethylene glycol)-b-poly(ε-caprolactone (PEG-b-PCL)) | In vitro | Not specified | Not applicable | initial burst of drug release, followed by sustained release of docetaxel | Mikhail and Allen (2010) |
Docetaxel | Solid dispersion | Polyvinylpyrrolidone, polyvinylpyrrolidone vinyl acetate copolymer, Tert-butanol, sodium lauryl sulfate and dimethyl sulfoxide, polysorbate 80, sorbitan monooleate, polyethylene glycol | In vivo, in vitro and phase I study | Not specified | 15 mg capsule daily by oral administration | Enhanced solubility and dissolution when compared with docetaxel | Moes et al. (2011) |
Docetaxel | Polymeric micelle | mPEG2000-DSPE | In vitro and in vivo (mice) | Breast, ovarian and lung cancer | Intravenous | Similar antitumor activity in -vitro and enhanced cytotoxic effect in vivo when compared with taxotere | Tong et al. (2012) |
Docetaxel | Polymeric micelle | Poly (lactic acid) (PLA)-polyethyleneglycol (PEG), folate | In vitro study | Not specified | Freeze dried products for various use | Sustained drug release, reduced cytotoxic effect compared with free docetaxel | Hami et al. (2014) |
Docetaxel | Nano-lipid suspension | Soy phosphatidylcholine, sodium cholesteryl sulfate | Randomized human study | Metastatic breast cancer | I.V. Infusion of 75 mg/m2 administered over an hour | Greater therapeutic efficacy (35%) when compared with taxotere (26.3%) | Ahmad et al. (2014) |
Docetaxel | Aqueous based nano-suspension | Soy phosphatidylcholine, Sodium Cholesteryl Sulfate, sodium citrate buffer, Sucrose solution | In vivo study | Advanced solid tumors | Albino mice at 5–15 mg/kg, and Sprague Dawley rats at 0.312 = 1.25 mg/kg, | Higher systemic bioavailability compared with taxotere | Ahmad et al. (2015) |
Docetaxel | Nano-formulation | Dimethyl sulfoxide(DMSO) Calcium carbonate, | In vitro | Breast cancer | Suspension for various use | Sustained release at 7.4, cytotoxicity comparable with docetaxel | Hammadi et al. (2017) |
Docetaxel | Polymeric micelle | Poly(styrene-maleic acid) (SMA), poly (amide-ether-ester-imide)-poly ethylene glycol (PAEEI-PEG) | In vivo study | Breast cancer | Intravenous | More stable formulation with high cytotoxicity and enhanced anticancer activity | Varshosaz et al. (2018) |
Docetaxel | Nano-formulation | Dimethyl sulfoxide(DMSO) Calcium carbonate, | In vitro | Not specified | Oral | Sustained drug release for up to 24 h | Kim et al. (2019) |
Docetaxel | Polymeric micelle | N-(tert-butoxycarbonyl)-l-phenylalanine end-capped methoxy-poly (ethylene glycol)-block-poly (d, l-lactide) (mPEG-b-PLA-Phe(Boc)) | In vitro and In vivo (mice) study | Non-small cell lung cancer | Intravenous | Targeted, sustained release formulation with greater efficacy than taxotere | Gong et al. (2020) |
Docetaxel | Nano-liposome | Phosphatidylserine and cholesterol | In vitro | Breast, head, neck and gastric cancer | Injectable | Sustained drug release for up to 13 h | Harwalkar et al. (2020) |
Docetaxel | Nano-emulsion | Low molecular weight methylcellulose, (DOCA) complexed with (DOTAP) (DOCA-yielding DOTAP [DA-TAP] complex) | In vivo (mice) | Not specified | Oral administration | Bioavailability increased by 249% when compared with taxotere | Jha et al. (2020) |
Docetaxel | Nano-liposome | HSPC, mPEG, DSPE, Cholesterol, DPPG, DSPG | In vivo (mice) | Breast cancer | 8 mg/kg body weight intravenously | Enhanced delivery to tumor with prolonged duration of action. High plasma stability was also observed | Vakili et al. (2020) |
Docetaxel | Micelle | Polysorbate, retinoic acid | Phase I and II | Breast cancer | 100 mg/m2 intravenous infusion administered for an hour | No prior administration of steroid necessary. Bioequivalence of micelles with taxotere was observed with similar safety profile | Joeger et al. (2020) |
Docetaxel | Solid binary inclusion complex | dimethyl-β-cyclodextrin (DM-β-C) | In vitro | Not specified | Oral | Aqueous solubility enhanced by 76.04 and in vitro dissolution by 3.55-fold | Giri et al. (2021) |